JP2018515605A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515605A5
JP2018515605A5 JP2018510322A JP2018510322A JP2018515605A5 JP 2018515605 A5 JP2018515605 A5 JP 2018515605A5 JP 2018510322 A JP2018510322 A JP 2018510322A JP 2018510322 A JP2018510322 A JP 2018510322A JP 2018515605 A5 JP2018515605 A5 JP 2018515605A5
Authority
JP
Japan
Prior art keywords
protein
composition
subject
ldl
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018510322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515605A (ja
JP6751756B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/031109 external-priority patent/WO2016179456A1/en
Publication of JP2018515605A publication Critical patent/JP2018515605A/ja
Publication of JP2018515605A5 publication Critical patent/JP2018515605A5/ja
Application granted granted Critical
Publication of JP6751756B2 publication Critical patent/JP6751756B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018510322A 2015-05-07 2016-05-06 低密度リポタンパク質コレステロールレベルを低下させるためのcd24の使用 Expired - Fee Related JP6751756B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158157P 2015-05-07 2015-05-07
US62/158,157 2015-05-07
PCT/US2016/031109 WO2016179456A1 (en) 2015-05-07 2016-05-06 Use of cd24 for lowering low-density lipoprotein cholesterol levels

Publications (3)

Publication Number Publication Date
JP2018515605A JP2018515605A (ja) 2018-06-14
JP2018515605A5 true JP2018515605A5 (cg-RX-API-DMAC7.html) 2019-04-11
JP6751756B2 JP6751756B2 (ja) 2020-09-09

Family

ID=57218627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510322A Expired - Fee Related JP6751756B2 (ja) 2015-05-07 2016-05-06 低密度リポタンパク質コレステロールレベルを低下させるためのcd24の使用

Country Status (18)

Country Link
US (2) US10369197B2 (cg-RX-API-DMAC7.html)
EP (1) EP3292144B1 (cg-RX-API-DMAC7.html)
JP (1) JP6751756B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170141216A (cg-RX-API-DMAC7.html)
CN (1) CN107531772B (cg-RX-API-DMAC7.html)
AU (1) AU2016258084B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017022394A2 (cg-RX-API-DMAC7.html)
CA (1) CA2982612A1 (cg-RX-API-DMAC7.html)
EA (1) EA038520B1 (cg-RX-API-DMAC7.html)
ES (1) ES2829235T3 (cg-RX-API-DMAC7.html)
HK (1) HK1249521A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20201651T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051866T2 (cg-RX-API-DMAC7.html)
IL (1) IL255086B (cg-RX-API-DMAC7.html)
MX (1) MX385941B (cg-RX-API-DMAC7.html)
PT (1) PT3292144T (cg-RX-API-DMAC7.html)
WO (1) WO2016179456A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201706846B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途
SG11201908077XA (en) * 2017-03-07 2019-09-27 Oncoimmune Inc Methods of use of soluble cd24 for treating systemic lupus erythematosus
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
US20210046154A1 (en) * 2018-03-05 2021-02-18 Oncoimmune, Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
TW202015753A (zh) * 2018-06-04 2020-05-01 美商昂科免疫公司 以cd24預防及治療移植物抗宿主病及黏膜炎之方法
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
WO2020163529A1 (en) * 2019-02-06 2020-08-13 Oncoimmune, Inc. Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis
US20220000974A1 (en) * 2019-02-06 2022-01-06 Oncolmmune, Inc. Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
US20230103352A1 (en) * 2020-02-10 2023-04-06 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection
EP4103217A4 (en) * 2020-02-10 2024-03-13 Oncoimmune Inc. METHOD OF USING SOLUBLE CD24 TO TREAT VIRAL PNEUMONIA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
CN1323544A (zh) * 2000-05-13 2001-11-28 蛋白质技术国际公司 降低低密度脂蛋白胆固醇浓度的组合物和方法
JP2011509244A (ja) * 2007-12-21 2011-03-24 ユニバーシティー オブ ロチェスター 脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのcd24
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
ES2826445T3 (es) * 2010-04-28 2021-05-18 Oncolmmune Inc Uso médico de CD24 soluble
US20140357505A1 (en) * 2011-06-10 2014-12-04 The Trustees Of The University Of Pennsylvania System And Method Of Cytomic Vascular Health Profiling
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途

Similar Documents

Publication Publication Date Title
JP7166478B2 (ja) ヒトヒアルロニダーゼph20の変異体及び薬物を含む皮下投与用医薬組成物
Lei et al. Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
Deng et al. Nav1. 7 is essential for nociceptor action potentials in the mouse in a manner independent of endogenous opioids
Veritti et al. Neovascular age-related macular degeneration
Schellekens Factors influencing the immunogenicity of therapeutic proteins
US7303748B2 (en) Method of treating eye injury with local administration of a VEGF inhibitor
Palmer et al. Liddle’s syndrome
Matsuka et al. Factor XIIIa-catalyzed cross-linking of recombinant αC fragments of human fibrinogen
Mancuso et al. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
Morar-Mitrica et al. Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration
Hermans et al. Recombinant factor VIII Fc for the treatment of haemophilia A
JP2018528237A (ja) 治療剤に対する免疫応答を除去するための改善された方法及び化合物
Richter et al. Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice
CN107531772A (zh) Cd24用于降低低密度脂蛋白胆固醇水平的用途
Sun et al. Gene delivery of activated factor VII using alternative adeno-associated virus serotype improves hemostasis in hemophiliac mice with FVIII inhibitors and adeno-associated virus neutralizing antibodies
Sankar et al. The evolution of recombinant factor replacement for hemophilia
JP2016530284A (ja) 疾患及び障害を治療するためにインターロイキン−10を使用する方法
Jiang et al. 2025 clinical trials update on hemophilia, VWD, and rare inherited bleeding disorders
Valentino et al. The biological efficacy profile of BAX 855, a PEG ylated recombinant factor VIII molecule
Garger et al. BAY 81‐8973, a full‐length recombinant factor VIII: manufacturing processes and product characteristics
Santagostino A new recombinant factor VIII: from genetics to clinical use
Chintalgattu et al. Utility of Glycosylated TIMP3 molecules: Inhibition of MMPs and TACE to improve cardiac function in rat myocardial infarct model
Akhtar et al. Molecular basis of proteinuria
JP2019506408A5 (cg-RX-API-DMAC7.html)
Ijima et al. Successful gene therapy via intraarticular injection of adenovirus vector containing CTLA4IgG in a murine model of type II collagen-induced arthritis